Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung
暂无分享,去创建一个
J. Blay | R. Schilsky | S. Ikeda | B. Solomon | E. Felip | J. Tabernero | R. Kurzrock | G. Batist | I. Berindan‐Neagoe | G. Berchem | A. Porgador | E. Rubin | J. Martini | S. Galbraith | A. Onn | C. Bresson | T. Philip | U. Lassen | Shai Magidi | Amal Al-Omari | C. Pramesh | V. Lazar | Nicolas Girard | Jacques Raynaud | F. Wunder | J. Raynaud | N. Girard | Vladimir Lazar
[1] Edward S. Kim,et al. Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes , 2021, Scientific Reports.
[2] S. Peters,et al. Severity of COVID-19 in patients with lung cancer: evidence and challenges , 2021, Journal for ImmunoTherapy of Cancer.
[3] R. Kurzrock,et al. Balancing clinical evidence in the context of a pandemic , 2021, Nature Biotechnology.
[4] H. B. Baghi,et al. SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis , 2021, Life Sciences.
[5] R. Kurzrock,et al. The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers. , 2020, Journal of immunotherapy and precision oncology.
[6] Katie M. Campbell,et al. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. , 2020, Cancer discovery.
[7] T. Wegman-Ostrosky,et al. ACE2: the molecular doorway to SARS-CoV-2 , 2020, Cell & Bioscience.
[8] Habiba S. Alsafar,et al. Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection , 2020, Molecular Therapy - Methods & Clinical Development.
[9] Chin Yee Tan,et al. Transcriptional and proteomic insights into the host response in fatal COVID-19 cases , 2020, Proceedings of the National Academy of Sciences.
[10] C. Deutschman,et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes , 2020, The Lancet Respiratory Medicine.
[11] L. Brochez,et al. IDO Expression in Cancer: Different Compartment, Different Functionality? , 2020, Frontiers in Immunology.
[12] R. Kurzrock,et al. Transcriptomics and Solid Tumors: The Next Frontier in Precision Cancer Medicine. , 2020, Seminars in cancer biology.
[13] Zeyu Chen,et al. T cell responses in patients with COVID-19 , 2020, Nature Reviews Immunology.
[14] Sasikanth Manne,et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.
[15] Zhenghao Xu,et al. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies , 2020, Frontiers in Immunology.
[16] B. Autran,et al. Cell-Mediated Immune Responses to COVID-19 Infection , 2020, Frontiers in Immunology.
[17] E. Robilotti,et al. Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.
[18] W. Turski,et al. AhR and IDO1 in pathogenesis of Covid-19 and the “Systemic AhR Activation Syndrome:” a translational review and therapeutic perspectives , 2020, Restorative neurology and neuroscience.
[19] G. Middleton,et al. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome? , 2020, British Journal of Cancer.
[20] M. Lenardo,et al. A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.
[21] J. Wolchok,et al. Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers , 2020, Cancer discovery.
[22] R. Kurzrock,et al. Repurposing Interleukin-6 Inhibitors to Combat COVID-19. , 2020, Journal of immunotherapy and precision oncology.
[23] R. Kurzrock,et al. Are Cancer Patients at Higher Risk of Death With COVID-19? , 2020, Journal of immunotherapy and precision oncology.
[24] Fabian J Theis,et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.
[25] Jinlyu Sun,et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19 , 2020, Journal of Autoimmunity.
[26] Amber Dance. What is a cytokine storm? , 2020 .
[27] Fabian J Theis,et al. SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways , 2020, Nature Medicine.
[28] M. Letko,et al. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.
[29] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[30] E. Hays,et al. Cell-mediated immune resistance in cancer , 2020, Cancer drug resistance.
[31] C. Solinas,et al. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy , 2020, ESMO Open.
[32] Camille Guillerey,et al. TIGIT as an emerging immune checkpoint , 2019, Clinical and experimental immunology.
[33] Yong Liu,et al. TOX is a critical regulator of tumour-specific T cell differentiation , 2019, Nature.
[34] J Jack Lee,et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial , 2019, Nature Medicine.
[35] J. Allison,et al. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.
[36] J. Stumhofer,et al. ICOS Co-Stimulation: Friend or Foe? , 2016, Front. Immunol..
[37] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[38] Pierre Validire,et al. Integrated molecular portrait of non-small cell lung cancers , 2013, BMC Medical Genomics.
[39] Virginia Pascual,et al. Induction of ICOS+CXCR3+CXCR5+ TH Cells Correlates with Antibody Responses to Influenza Vaccination , 2013, Science Translational Medicine.
[40] William N. Venables,et al. Modern Applied Statistics with S , 2010 .
[41] John L. Sullivan,et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.
[42] Andreas Hutloff,et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28 , 1999, Nature.